The human body is a complex assembly of physiological systems designed to manage the multidirectional transport of both information and nutrients. An intricate interplay between the nervous, circulatory, and secretory systems is therefore necessary to sustain life, allow delivery of nutrients and therapeutic drugs, and eliminate metabolic waste products and toxins. These systems also provide vulnerable routes for modification by substances of abuse. Addictive substances are, by definition, neurologically active, but as they and their metabolites are spread throughout the body via the nervous, circulatory, respiratory and digestive systems, there is abundant opportunity for interaction with numerous cell and tissue types. Cocaine is one such substance that exerts a broad physiological effect. While a great deal of the research concerning addiction has addressed the neurological effects of cocaine use, only a few studies have been aimed at delineating the role that cocaine plays in various body systems. In this paper, we probe the current research regarding cocaine and the immune system, and map a systems-level view to outline a broader perspective of the biological response to cocaine. Specifically, our overview of the neurological and immunomodulatory effects of the drug will allow a broader perspective of the biological response to cocaine. The focus of this review is on the connection between the nervous and immune systems and the role this connection plays in the long-term complications of cocaine use. By describing the multiplicity of these connections, we hope to inspire detailed investigations into the immunological interplay in cocaine addiction.
BeaulieuJMGainetdinovRR. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev2011; 63: 182–217.
2.
LawPYWongYHLohHH. Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol2000; 40: 389–430.
3.
NestlerEJ. Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol Sci2004; 25: 210–8.
4.
World Health Organization. Neuroscience of psychoactive substance use and dependence, Geneva: World Health Organization, 2004.
5.
QuanNBanksWA. Brain-immune communication pathways. Brain Behav Immun2007; 21: 727–35.
6.
GoedersNE. The HPA axis and cocaine reinforcement. Psychoneuroendocrinology2002; 27: 13–33.
7.
StraubRH. Complexity of the bi-directional neuroimmune junction in the spleen. Trends Pharmacol Sci2004; 25: 640–6.
8.
DeleoJATangaFYTawfikVL. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist2004; 10: 40–52.
9.
HeeschCMNegusBHKefferJHSnyderRWIRisserRCEichhornEJ. Effects of cocaine on cortisol secretion in humans. Am J Med Sci1995; 310: 61–4.
10.
GoedersNE. A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology1997; 22: 237–59.
11.
GoedersNEBienvenuOJDesouzaEB. Chronic cocaine administration alters corticotropin-releasing factor receptors in the rat-brain. Brain Res1990; 531: 322–8.
12.
HutchinsonMRShavitYGracePMRiceKCMaierSFWatkinsLR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev2011; 63: 772–810.
13.
GhoshCMarchiNHossainMRasmussenPAlexopoulosAVGonzalez-MartinezJYangHJanigroD. A pro-convulsive carbamazepine metabolite: quinolinic acid in drug resistant epileptic human brain. Neurobiol Dis2012; 46: 692–700.
14.
RobbinsTWEverittBJ. Drug addiction: bad habits add up. Nature1999; 398: 567–70.
15.
CivelliOBunzowJRGrandyDK. Molecular diversity of the dopamine-receptors. Annu Rev Pharmacol Toxicol1993; 33: 281–307.
16.
DalleyJWEverittBJ. Dopamine receptors in the learning, memory and drug reward circuitry. Semin Cell Dev Biol2009; 20: 403–10.
17.
NestlerEJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol1997; 7: 713–9.
BlakelyRDDeFeliceLJHartzellHC. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol1994; 196: 263–81.
20.
SchoemakerHPimouleCArbillaSScattonBJavoyagidFLangerSZ. Sodium-dependent [H-3] cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons-Disease. Naunyn Schmiedebergs Arch Pharmacol1985; 329: 227–35.
21.
ZhangHSulzerD. Regulation of striatal dopamine release by presynaptic auto- and heteroreceptors. Basal Ganglia2012; 2: 5–13.
22.
CraggSJGreenfieldSA. Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. J Neurosci1997; 17: 5738–46.
23.
BelloEPMateoYGelmanDMNoainDShinJHLowMJAlvarezVALovingerDMRubinsteinM. Cocaine supersensitivity and enhanced motivation for reward in mice lacking dopamine D-2 autoreceptors. Nat Neurosci2011; 14: 1033–8.
24.
KoobGFVolkowND. Neurocircuitry of addiction. Neuropsychopharmacol2010; 35: 217–38.
25.
VolkowNDWangGJFowlerJSTomasiDTelangF. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci U S A2011; 108: 15037–42.
26.
EverittBJDickinsonARobbinsTW. The neuropsychological basis of addictive behaviour. Brain Res Rev2001; 36: 129–38.
27.
HymanSEMalenkaRCNestlerEJ. Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci2006; 29: 565–98.
28.
WheelerRAAragonaBJFuhrmannKAJonesJLDayJJCacciapagliaFWightmanRMCarelliRM. Cocaine cues drive opposing context-dependent shifts in reward processing and emotional state. Biol Psychiatry2011; 69: 1067–74.
29.
AragonaBJDayJJRoitmanMFCleavelandNAWightmanRMCarelliRM. Regional specificity in the real-time development of phasic dopamine transmission patterns during acquisition of a cue-cocaine association in rats. Eur J Neurosci2009; 30: 1889–99.
30.
WiseRAKiyatkinEA. Differentiating the rapid actions of cocaine. Nat Rev Neurosci2011; 12: 479–84.
SmirnovMSKiyatkinEA. Cocaine action on peripheral, non-monoamine neural substrates as a trigger of electroencephalographic desynchronization and electromyographic activation following IV administration in freely moving rats. Neuroscience2010; 165: 500–14.
33.
UnterwaldEMRubenfeldJMKreekMJ. Repeated cocaine administration up-regulates kappa-opioid and mu-opioid, but not delta-opioid receptors. NeuroReport1994; 5: 1613–6.
34.
MartinWREadesCGThompsonJAHupplerREGilbertPE. Effects of morphine-like and nalorphine-like drugs in nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther1976; 197: 517–32.
35.
VaupelDB. Naltrexone fails to antagonize the sigma-effects of PCP and SKF 10,047 in the dog. Eur J Pharmacol1983; 92: 269–74.
36.
SuTPHayashiT. Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem2003; 10: 2073–80.
37.
HayashiTSuTP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca2+ signaling and cell survival. Cell2007; 131: 596–610.
38.
MauriceTSuTP. The pharmacology of sigma-1 receptors. Pharmacol Ther2009; 124: 195–206.
39.
SuTPHayashiT. Cocaine affects the dynamics of cytoskeletal proteins via sigma(1) receptors. Trends Pharmacol Sci2001; 22: 456–8.
40.
SuTPHayashiTVaupelDB. When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor. Sci Signal2009; 2: pe12–pe12.
41.
HayashiTSuTP. Regulating ankyrin dynamics: roles of sigma-1 receptors. Proc Natl Acad Sci U S A2001; 98: 491–6.
42.
SabetiJNelsonTEPurdyRHGruolDL. Steroid pregnenolone sulfate enhances NMDA-receptor-independent long-term potentiation at hippocampal CA1 synapses: role for L-type calcium channels and sigma-receptors. Hippocampus2007; 17: 349–69.
43.
MartinaMTurcotteMEBHalmanSBergeronR. The sigma-1 receptor modulates NMDA receptor synaptic transmission and plasticity via SK channels in rat hippocampus. J Physiol2007; 578: 143–57.
44.
ChenLDaiXNSokabeM. Chronic administration of dehydroepiandrosterone sulfate (DHEAS) primes for facilitated induction of long-term potentiation via sigma 1 (sigma(1)) receptor: optical imaging study in rat hippocampal slices. Neuropharmacology2006; 50: 380–92.
45.
HayashiTSuTP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs2004; 18: 269–84.
46.
MatsumotoRRMcCrackenKAPouwBZhangYBowenWD. Involvement of sigma receptors in the behavioral effects of cocaine: evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology2002; 42: 1043–55.
47.
LiuYMatsumotoRR. Alterations in fos-related antigen 2 and sigma(1) receptor gene and protein expression are associated with the development of cocaine-induced behavioral sensitization: time course and regional distribution studies. J Pharmacol Exp Ther2008; 327: 187–95.
48.
LiuYChenGDLernerMRBrackettDJMatsumotoRR. Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J Pharmacol Exp Ther2005; 314: 770–9.
49.
WatsonESMurphyJCElsohlyHNElsohlyMATurnerCE. Effects of the administration of coca alkaloids on the primary immune-responses of mice – interaction with delta-9-tetrahydrocannabinol and ethanol. Toxicol Appl Pharmacol1983; 71: 1–13.
50.
BagasraOFormanL. Functional-analysis of lymphocytes subpopulations in experimental cocaine abuse .1. Dose-dependent activation of lymphocyte subsets. Clin Exp Immunol1989; 77: 289–93.
51.
RothMDWhittakerKMChoiRTashkinDPBaldwinGC. Cocaine and sigma-1 receptors modulate HIV infection, chemokine receptors, and the HPA axis in the huPBL-SCID model. J Leukoc Biol2005; 78: 1198–203.
52.
ChaoCJacobsonLPTashkinDMartinez-MazaORothMDMargolickJBChmielJSRinaldoCZhangZFDetelsR. Recreational drug use and T lymphocyte subpopulations in HIV-uninfected and HIV-infected men. Drug Alcohol Depend2008; 94: 165–71.
53.
KleinTWMatsuiKNewtonCAYoungJWidenREFriedmanH. Cocaine suppresses proliferation of phytohemagglutinin-activated human peripheral-blood T-cells. Int J Immunopharmacol1993; 15: 77–86.
54.
PiccottiJRBrissetteStorkusCSChambersWHBrickerJD. Suppression of splenic T lymphocyte proliferation by acute cocaine administration. Life Sci1997; 61: 967–76.
55.
FarajBAOlkowskiZLJacksonRT. A cocaine-sensitive active dopamine transport in human-lymphocytes. Biochem Pharmacol1995; 50: 1007–14.
56.
BaldwinGCRothMDTashkinDP. Acute and chronic effects of cocaine on the immune system and the possible link to AIDS. J Neuroimmunol1998; 83: 133–8.
57.
GardnerBZhuLXRothMDTashkinDPDubinettSMSharmaS. Cocaine modulates cytokine and enhances tumor growth through sigma receptors. J Neuroimmunol2004; 147: 95–8.
58.
GanXHZhangLNewtonTChangSLLingWKermaniVBergerOGravesMCFialaM. Cocaine infusion increases interferon-gamma and decreases interleukin-10 in cocaine-dependent subjects. Clin Immunol Immunopathol1998; 89: 181–90.
59.
PellegrinoTBayerBM. In vivo effects of cocaine on immune cell function. J Neuroimmunol1998; 83: 139–47.
60.
KuberaMFilipMBasta-KaimANowakESiwanowiczJZajicovaAHolanVMaesMLasoriW. The effect of cocaine sensitization on mouse immunoreactivity. Eur J Pharmacol2004; 483: 309–15.
61.
PellegrinoTCDunnKLBayerBM. Mechanisms of cocaine-induced decreases in immune cell function. Int Immunopharmacol2001; 1: 665–75.
62.
DengSXBharatNFischmanMCLandryDW. Covalent modification of proteins by cocaine. Proc Natl Acad Sci U S A2002; 99: 3412–6.
63.
SchneiderKJDeCaprioAP. Covalent thiol adducts arising from reactive intermediates of cocaine biotransformation. Chem Res Toxicol2013; 26: 1755–64.
OrsonFMRossenRDShenXLopezAYWuYKostenTR. Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. Am J Addiction2013; 22: 169–74.
66.
KostenTRDomingoCB. Can you vaccinate against substance abuse?Expert Opin Biol Ther2013; 13: 1093–7.
67.
KousikSMNapierTCCarveyPM. The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Front Pharmacol2012; 3: 121–121.
RothMDTashkinDPChoiRJamiesonBDZackJABaldwinGC. Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis2002; 185: 701–5.
70.
KimSGJungJBDixitDRovnerRZackJABaldwinGCVatakisDN. Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection. J Leukoc Biol2013; 94: 835–43.
XuWFlickTMitchelJKnowlesCAultK. Cocaine effects on immunocompetent cells: an observation of in vitro cocaine exposure. Int J Immunopharmacol1999; 21: 463–72.
73.
FischmanMWSchusterCRJavaidJHatanoYDavisJ. Acute tolerance development to the cardiovascular and subjective effects of cocaine. J Pharmacol Exp Ther1985; 235: 677–82.
74.
PittsDKUdomCEMarwahJ. Cardiovascular effects of cocaine in anesthetized and conscious rats. Life Sci1987; 40: 1099–111.
75.
FoltinRWFischmanMW. Smoked and intravenous cocaine in humans – acute tolerance, cardiovascular and subjective effects. J Pharmacol Exp Ther1991; 257: 247–61.
76.
MendelsonJHSholarMMelloNKTeohSKSholarJW. Cocaine tolerance: behavioral, cardiovascular, and neuroendocrine function in men. Neuropsychopharmacol1998; 18: 263–71.
77.
KarchSB. Cocaine cardiovascular toxicity. South Med J2005; 98: 794–9.
KalivasPWStewartJ. Dopamine transmission in the initiation and expression of drug-induced and stress-induced sensitization of motor-activity. Brain Res Rev1991; 16: 223–44.
90.
De VriesTJSchoffelmeerANMBinnekadeRMurderAHVanderschurenLJMJ. Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. Eur J Neurosci1998; 10: 3565–71.
91.
RomieuPMeunierJGarciaDZozimeNMartin-FardonRBowenWDMauriceT. The sigma(1) (sigma(1)) receptor activation is a key step for the reactivation of cocaine conditioned place preference by drug priming. Psychopharmacol2004; 175: 154–62.
92.
EckeLECleckJNWhitePSchugJMifflinLBlendyJA. CREB-mediated alterations in the amygdala transcriptome: coordinated regulation of immune response genes following cocaine. Int J Neuropsychopharmacol2011; 14: 1111–26.
93.
MaierSFWatkinsLR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev1998; 105: 83–107.
94.
AnismanH. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci2009; 34: 4–20.
95.
SternbergEM. Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol2006; 6: 318–28.
96.
Tilders JH, Schmidt ED. Cross-sensitization between immune and non-immune stressors. In: Dantzer R, Wollman EE, Yirmiya R (eds) Cytokines, stress, and depression. 461 ed. New York: Springer, 1999, pp.179–97.
97.
AmbroggiFTuriaultMMiletADeroche-GamonetVParnaudeauSBaladoEBarikJvan der VeenRMaroteauxGLembergerTSchutzGLazarMMarinelliMPiazzaPVTroncheF. Stress and addiction: glucocorticoid receptor in dopaminoceptive neurons facilitates cocaine seeking. Nat Neurosci2009; 12: 247–9.
98.
AvilaAHAlonzoNCBayerBMEffects of cocaine and morphine withdrawal on the immune response. In: FriedmanHKleinTWBendinelliM (eds). Infectious diseases and substance abuse, New York: Springer, 2005, pp. 1–11.
99.
AvilaAHMorganCABayerBM. Stress-induced suppression of the immune system after withdrawal from chronic cocaine. J Pharmacol Exp Ther2003; 305: 290–7.
100.
AvilaAHAlonzoNCBayerBM. Immune cell activity during the initial stages of withdrawal from chronic exposure to cocaine or morphine. J Neuroimmunol2004; 147: 109–13.
101.
JohnsonTRKniselyJSChristmasJTSchnollSHRuddyS. Changes in immunologic cell surface markers during cocaine withdrawal in pregnant women. Brain Behav Immun1996; 10: 324–36.
102.
PacificiRZuccaroPFarreMPichiniSDi CarloSRosetPNPalmiIOrtunoJMenoyoESeguraJde la TorreR. Cell-mediated immune response in MDMA users after repeated dose administration. Ann New York Acad Sci2002; 965: 421–33.
103.
HicksMJDeBPRosenbergJBDavidsonJTMorenoAYJandaKDWeeSKoobGFHackettNRKaminskySMWorgallSTothMMezeyJCrystalRG. Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther2011; 19: 612–9.
